Neurosteer

Executive Summary

Neurosteer is an Israeli medtech company specializing in a wearable, medical-grade high-definition EEG (hdrEEG) platform that integrates a compact sensor with AI-driven signal analysis to deliver real-time, objective biomarkers for brain health. Founded in 2015 and headquartered in Tel Aviv, the company targets early detection and continuous monitoring of neurodegenerative diseases, epilepsy, mental health conditions, pain, and neonatal neurology. By enabling non-invasive, at-home assessments, Neurosteer aims to shift brain health diagnostics from episodic clinic visits to continuous, decentralized care. The platform's AI decomposes EEG signals into actionable insights, potentially improving diagnostic accuracy, treatment optimization, and disease progression tracking. With a team of 50-200 employees and a platform-stage business model, Neurosteer competes in the rapidly growing digital neurology market, where demand for remote monitoring and objective biomarkers is surging. The company's technology has broad applicability across multiple therapeutic areas, offering a versatile tool for clinicians and patients alike. While specific funding and valuation details are undisclosed, Neurosteer's focus on high-need neurological conditions and its proprietary AI-EEG approach position it as a potential leader in the wearable brain health space. The company's strategy likely involves regulatory clearances (e.g., FDA) and strategic partnerships with healthcare providers or pharmaceutical companies to validate and commercialize its platform.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for first indication (e.g., epilepsy monitoring)65% success
• H1 2027Strategic partnership with a major pharma or neurology clinic for clinical validation60% success
• Q2 2027Launch of a CE-marked product in Europe for neurodegenerative disease monitoring55% success